Literature DB >> 22741932

Management of cutaneous dermatomyositis.

Christina Lam1, Ruth Ann Vleugels.   

Abstract

Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22741932     DOI: 10.1111/j.1529-8019.2012.01491.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  7 in total

1.  Identification of Biomarkers Associated With CD4+ T-Cell Infiltration With Gene Coexpression Network in Dermatomyositis.

Authors:  Peng Huang; Li Tang; Lu Zhang; Yi Ren; Hong Peng; Yangyang Xiao; Jie Xu; Dingan Mao; Lingjuan Liu; Liqun Liu
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

2.  [Therapy of myositis].

Authors:  A D Keck; U A Walker
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

3.  Unilateral heliotrope rash in juvenile dermatomyositis: an unusual presentation of an underlying serious disease.

Authors:  Ghada Al-Janobi; Hisham Alkhalidi; Mohammed A Omair
Journal:  Case Rep Rheumatol       Date:  2014-12-22

4.  The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy.

Authors:  C O Anyanwu; P B Chansky; R Feng; K Carr; J Okawa; V P Werth
Journal:  Int J Womens Dermatol       Date:  2017-06-13

Review 5.  The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.

Authors:  Anjali Patwardhan
Journal:  Cureus       Date:  2020-02-19

6.  Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study.

Authors:  Adarsh Ravishankar; Daisy Yan; Christina E Bax; Josef S Concha; Rui Feng; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2020-07-23       Impact factor: 11.527

7.  Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index.

Authors:  Peter B Chansky; Jeannette M Olazagasti; Rui Feng; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2017-10-21       Impact factor: 15.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.